Gilead Sciences, Inc. (GILD) Stock Analysis
Healthcare · Drug Manufacturers - General
Hold if already holding. Not a fresh buy at $130.61, but acceptable to hold if already in. Reasons: Concentration risk — Customer: Cardinal Health, Cencora, McKesson (90.0%); Concentration risk — Product: HIV.
Gilead Sciences is a biopharmaceutical company with 25+ commercial products across HIV (Biktarvy, Descovy), viral hepatitis (Epclusa, Vemlidy), and oncology (Yescarta, Trodelvy), operating in 35+ countries. HIV products generate a substantial portion of revenue, distributed... Read more
Hold if already holding. Not a fresh buy at $130.61, but acceptable to hold if already in. Reasons: Concentration risk — Customer: Cardinal Health, Cencora, McKesson (90.0%); Concentration risk — Product: HIV. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 6.4/10, moderate confidence.
Passes 4/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and earnings proximity 6d<=7d. Suitability: conservative.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerCardinal Health, Cencora, McKesson90%10-K Item 1A: 'approximately 90% of our gross product sales in the U.S. have been to three wholesalers—Cardinal Health, Inc., Cencora, Inc. and McKesson Corporation'
- HIGHProductHIV10-K Item 1A: 'We receive a substantial portion of our revenue from sales of our products for the treatment and prevention of HIV infection'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $130.61, but acceptable to hold if already in. Reasons: Concentration risk — Customer: Cardinal Health, Cencora, McKesson (90.0%); Concentration risk — Product: HIV. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $142.52 (+9.1%), stop $124.50 (−4.9%), A.R:R 1.8:1. Score 6.4/10, moderate confidence.
Take-profit target: $142.52 (+9.1% upside). Target $142.52 (+9.1%), stop $124.50 (−4.9%), A.R:R 1.8:1. Stop-loss: $124.50.
Concentration risk — Customer: Cardinal Health, Cencora, McKesson (90.0%); Concentration risk — Product: HIV; Thin upside margin: 9.1%.
Gilead Sciences, Inc. trades at a P/E of 19.3 (forward 13.6). TrendMatrix value score: 7.3/10. Verdict: Hold.
39 analysts cover GILD with a consensus score of 4.1/5. Average price target: $158.
What does Gilead Sciences, Inc. do?Gilead Sciences is a biopharmaceutical company with 25+ commercial products across HIV (Biktarvy, Descovy), viral...
Gilead Sciences is a biopharmaceutical company with 25+ commercial products across HIV (Biktarvy, Descovy), viral hepatitis (Epclusa, Vemlidy), and oncology (Yescarta, Trodelvy), operating in 35+ countries. HIV products generate a substantial portion of revenue, distributed primarily through three U.S. wholesalers (Cardinal Health, Cencora, McKesson).